{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:30Z","timestamp":1790957550326,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Beta-adrenergic blocking agents (abbreviated as beta-blockers) have been used for treating various cardiovascular diseases. However, the potential for asthma exacerbation is one of the major adverse effects of beta-blockers. This study aimed to compare the level of risk for an asthma attack in patients receiving various beta-blockers. We searched for randomized controlled trials (RCTs) of either placebo-controlled or active-controlled design. The current network meta-analysis (NMA) was conducted under a frequentist model. The primary outcome was the incidence of asthmatic attack. A total of 24 RCTs were included. Overall NMA revealed that only oral timolol [risk ratio (RR)\u2009=\u20093.35 (95% confidence interval (CI) 1.04\u201310.85)] and infusion of propranolol [RR\u2009=\u200910.19 (95% CI 1.29\u201380.41)] were associated with significantly higher incidences of asthma attack than the placebo, whereas oral celiprolol [RR\u2009=\u20090.39 (95% CI 0.04\u20134.11)], oral celiprolol and propranolol [RR\u2009=\u20090.46 (95% CI 0.02\u201311.65)], oral bisoprolol [RR\u2009=\u20090.46 (95% CI 0.02\u201311.65)], oral atenolol [RR\u2009=\u20090.51 (95% CI 0.20\u20131.28)], infusion of practolol [RR\u2009=\u20090.80 (95% CI 0.03\u201325.14)], and infusion of sotalol [RR\u2009=\u20090.91 (95% CI 0.08\u201310.65)] were associated with relatively lower incidences of asthma attack than the placebo. In participants with a baseline asthma history, in addition to oral timolol and infusion of propranolol, oral labetalol, oxprenolol, propranolol, and metoprolol exhibited significantly higher incidences of asthma attack than did the placebo. In conclusion,\u00a0oral timolol and infusion of propranolol were associated with a significantly higher risk of developing an asthma attack in patients, especially in those with a baseline asthma history, and should be avoided in patients who present a risk of asthma.<\/jats:p><jats:p><jats:bold>Trial registration:<\/jats:bold> PROSPERO CRD42020190540.<\/jats:p>","DOI":"10.1038\/s41598-020-79837-3","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T11:49:18Z","timestamp":1610365758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials"],"prefix":"10.1038","volume":"11","author":[{"given":"Kuo-Yang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Pin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka J.","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsiung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"79837_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James, P. A. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507\u2013520 (2014).","journal-title":"JAMA"},{"key":"79837_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/CRD.0000000000000197","volume":"26","author":"A Kukin","year":"2018","unstructured":"Kukin, A., Noel, Z. R. & Watson, K. Through the decades: Beta-blocker use and outcomes in acute coronary syndromes. Cardiol. Rev. 26, 157\u2013166 (2018).","journal-title":"Cardiol. Rev."},{"key":"79837_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jama.2015.7505","volume":"314","author":"EN Prystowsky","year":"2015","unstructured":"Prystowsky, E. N., Padanilam, B. J. & Fogel, R. I. Treatment of atrial fibrillation. JAMA 314, 278\u2013288 (2015).","journal-title":"JAMA"},{"key":"79837_CR4","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","volume":"390","author":"M Metra","year":"2017","unstructured":"Metra, M. & Teerlink, J. R. Heart failure. Lancet 390, 1981\u20131995 (2017).","journal-title":"Lancet"},{"key":"79837_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3109\/02770903.2012.719252","volume":"49","author":"TH Self","year":"2012","unstructured":"Self, T. H., Wallace, J. L. & Soberman, J. E. Cardioselective beta-blocker treatment of hypertension in patients with asthma: When do benefits outweigh risks?. J. Asthma. 49, 947\u2013951 (2012).","journal-title":"J. Asthma."},{"key":"79837_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1378\/chest.13-1235","volume":"145","author":"DR Morales","year":"2014","unstructured":"Morales, D. R., Jackson, C., Lipworth, B. J., Donnan, P. T. & Guthrie, B. Adverse respiratory effect of acute beta-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 145, 779\u2013786 (2014).","journal-title":"Chest"},{"key":"79837_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.7326\/0003-4819-137-9-200211050-00035","volume":"137","author":"SR Salpeter","year":"2002","unstructured":"Salpeter, S. R., Ormiston, T. M. & Salpeter, E. E. Cardioselective beta-blockers in patients with reactive airway disease: A meta-analysis. Ann. Intern. Med. 137, 715\u2013725 (2002).","journal-title":"Ann. Intern. Med."},{"issue":"Suppl 1","key":"79837_CR8","first-page":"1","volume":"69","author":"British Thoracic Society & Scottish Intercollegiate Guidelines Network","year":"2014","unstructured":"British Thoracic Society & Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 69(Suppl 1), 1\u2013192 (2014).","journal-title":"Thorax"},{"key":"79837_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1800345","volume":"381","author":"SC Christiansen","year":"2019","unstructured":"Christiansen, S. C. & Zuraw, B. L. Treatment of hypertension in patients with asthma. N. Engl. J. Med. 381, 1046\u20131057 (2019).","journal-title":"N. Engl. J. Med."},{"key":"79837_CR10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross, D. S. et al. 2016 American thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 26, 1343\u20131421 (2016).","journal-title":"Thyroid."},{"key":"79837_CR11","doi-asserted-by":"publisher","first-page":"l4485","DOI":"10.1136\/bmj.l4485","volume":"366","author":"V Shanker","year":"2019","unstructured":"Shanker, V. Essential tremor: Diagnosis and management. BMJ 366, l4485 (2019).","journal-title":"BMJ"},{"key":"79837_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4254\/wjh.v6.i6.363","volume":"6","author":"C Triantos","year":"2014","unstructured":"Triantos, C. & Kalafateli, M. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis. World J. Hepatol. 6, 363\u2013369 (2014).","journal-title":"World J. Hepatol."},{"key":"79837_CR13","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.jacc.2010.02.015","volume":"55","author":"LF Hiratzka","year":"2010","unstructured":"Hiratzka, L. F. et al. 2010 ACCF\/AHA\/AATS\/ACR\/ASA\/SCA\/SCAI\/SIR\/STS\/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J. Am. Coll. Cardiol. 55, e27\u2013e129 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"79837_CR14","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/S0735-1097(01)01225-6","volume":"37","author":"J Chen","year":"2001","unstructured":"Chen, J., Radford, M. J., Wang, Y., Marciniak, T. A. & Krumholz, H. M. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J. Am. Coll. Cardiol. 37, 1950\u20131956 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"79837_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","volume":"15","author":"DR Morales","year":"2017","unstructured":"Morales, D. R., Lipworth, B. J., Donnan, P. T., Jackson, C. & Guthrie, B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: Population-based nested case control study. BMC Med. 15, 18 (2017).","journal-title":"BMC Med."},{"key":"79837_CR16","first-page":"2992","volume":"2","author":"S Salpeter","year":"2002","unstructured":"Salpeter, S., Ormiston, T. & Salpeter, E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst. Rev. 2, 2992 (2002).","journal-title":"Cochrane Database Syst. Rev."},{"key":"79837_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bcp.12181","volume":"77","author":"DW Loth","year":"2014","unstructured":"Loth, D. W. et al. beta-Adrenoceptor blockers and pulmonary function in the general population: The Rotterdam study. Br. J. Clin. Pharmacol. 77, 190\u2013200 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"79837_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(15)61478-7","volume":"386","author":"JP Higgins","year":"2015","unstructured":"Higgins, J. P. & Welton, N. J. Network meta-analysis: A norm for comparative effectiveness?. Lancet 386, 628\u2013630 (2015).","journal-title":"Lancet"},{"key":"79837_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 162, 777\u2013784 (2015).","journal-title":"Ann. Intern. Med."},{"key":"79837_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamapsychiatry.2018.4365","volume":"76","author":"YC Wu","year":"2019","unstructured":"Wu, Y. C. et al. Association of delirium response and safety of pharmacological interventions for the management and prevention of delirium: A network meta-analysis. JAMA Psychiatry. 76, 526\u2013535 (2019).","journal-title":"JAMA Psychiatry."},{"key":"79837_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/0022034519870466","volume":"98","author":"BS Zeng","year":"2019","unstructured":"Zeng, B. S. et al. Prevention of postdental procedure bacteremia: A network meta-analysis. J. Dent. Res. 98, 1204\u20131210 (2019).","journal-title":"J. Dent. Res."},{"key":"79837_CR22","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.smrv.2019.101235","volume":"50","author":"CP Yang","year":"2020","unstructured":"Yang, C. P. et al. Melatonergic agents in the prevention of delirium: A network meta-analysis of randomized controlled trials. Sleep Med. Rev. 50, 101235 (2020).","journal-title":"Sleep Med. Rev."},{"key":"79837_CR23","doi-asserted-by":"publisher","first-page":"e12663","DOI":"10.1111\/jpi.12663","volume":"69","author":"PT Tseng","year":"2020","unstructured":"Tseng, P. T. et al. The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J. Pineal Res. 69, e12663 (2020).","journal-title":"J. Pineal Res."},{"key":"79837_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1378\/chest.115.1.85","volume":"115","author":"ML Osborne","year":"1999","unstructured":"Osborne, M. L. et al. Lack of correlation of symptoms with specialist-assessed long-term asthma severity. Chest 115, 85\u201391 (1999).","journal-title":"Chest"},{"key":"79837_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"HK Reddel","year":"2009","unstructured":"Reddel, H. K. et al. An official American Thoracic Society\/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 180, 59\u201399 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"79837_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/hrt.40.2.184","volume":"40","author":"PB Decalmer","year":"1978","unstructured":"Decalmer, P. B., Chatterjee, S. S., Cruickshank, J. M., Benson, M. K. & Sterling, G. M. Beta-blockers and asthma. Br. Heart J. 40, 184\u2013189 (1978).","journal-title":"Br. Heart J."},{"key":"79837_CR27","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.1981.03310390060024","volume":"245","author":"RB Schoene","year":"1981","unstructured":"Schoene, R. B., Martin, T. R., Charan, N. B. & French, C. L. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA 245, 1460\u20131461 (1981).","journal-title":"JAMA"},{"key":"79837_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1089\/jop.1993.9.373","volume":"9","author":"TJ Zimmerman","year":"1993","unstructured":"Zimmerman, T. J. Topical ophthalmic beta blockers: A comparative review. J. Ocul. Pharmacol. 9, 373\u2013384 (1993).","journal-title":"J. Ocul. Pharmacol."},{"key":"79837_CR29","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1164\/rccm.201212-2206OC","volume":"187","author":"PM Short","year":"2013","unstructured":"Short, P. M., Williamson, P. A., Anderson, W. J. & Lipworth, B. J. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am. J. Respir. Crit. Care Med. 187, 1308\u20131314 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"79837_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/j.1552-4604.1986.tb02929.x","volume":"26","author":"D Sheppard","year":"1986","unstructured":"Sheppard, D. et al. Effects of esmolol on airway function in patients with asthma. J. Clin. Pharmacol. 26, 169\u2013174 (1986).","journal-title":"J. Clin. Pharmacol."},{"key":"79837_CR31","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1592\/phco.2005.25.11.1550","volume":"25","author":"MJ Barnett","year":"2005","unstructured":"Barnett, M. J., Milavetz, G. & Kaboli, P. J. beta-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease. Pharmacotherapy. 25, 1550\u20131559 (2005).","journal-title":"Pharmacotherapy."},{"key":"79837_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/ALN.0b013e3181e73eea","volume":"113","author":"RG Badgett","year":"2010","unstructured":"Badgett, R. G., Lawrence, V. A. & Cohn, S. L. Variations in pharmacology of beta-blockers may contribute to heterogeneous results in trials of perioperative beta-blockade. Anesthesiology 113, 585\u2013592 (2010).","journal-title":"Anesthesiology"},{"key":"79837_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","volume":"144","author":"JG Baker","year":"2005","unstructured":"Baker, J. G. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br. J. Pharmacol. 144, 317\u2013322 (2005).","journal-title":"Br. J. Pharmacol."},{"key":"79837_CR34","unstructured":"[Internet] go: The Global Initiative for Asthma. In. California; 2019."},{"key":"79837_CR35","unstructured":"[Internet] SIGNS: British Guideline on the Management of Asthma. SIGN 158. In. Edinburgh; 2019."},{"key":"79837_CR36","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.jaci.2007.09.029","volume":"120","author":"National Asthma Education and Prevention Program","year":"2007","unstructured":"National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J. Allergy Clin. Immunol. 120, S94-138 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"key":"79837_CR37","unstructured":"[Internet] NACAN: Australian Asthma Handbook. In. Melbourne; 2019."},{"key":"79837_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.alit.2016.12.005","volume":"66","author":"M Ichinose","year":"2017","unstructured":"Ichinose, M. et al. Japanese guidelines for adult asthma 2017. Allergol. Int. 66, 163\u2013189 (2017).","journal-title":"Allergol. Int."},{"key":"79837_CR39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1183\/09031936.93.05020196","volume":"5","author":"JC Pujet","year":"1992","unstructured":"Pujet, J. C., Dubreuil, C., Fleury, B., Provendier, O. & Abella, M. L. Effects of celiprolol, a cardioselective beta-blocker, on respiratory function in asthmatic patients. Eur. Respir. J. 5, 196\u2013200 (1992).","journal-title":"Eur. Respir. J."},{"issue":"Suppl 4","key":"79837_CR40","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1097\/00005344-198608004-00021","volume":"8","author":"R Schindl","year":"1986","unstructured":"Schindl, R., Wurtz, J. & Hoffmann, H. The effect of the cardioselective beta blocker celiprolol on pulmonary function in asthmatic patients. J. Cardiovasc. Pharmacol. 8(Suppl 4), S99-101 (1986).","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"Suppl 1","key":"79837_CR41","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S0954-6111(11)70010-5","volume":"105","author":"M Lainscak","year":"2011","unstructured":"Lainscak, M., Podbregar, M., Kovacic, D., Rozman, J. & von Haehling, S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir. Med. 105(Suppl 1), S44-49 (2011).","journal-title":"Respir. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79837-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79837-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79837-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T01:40:21Z","timestamp":1670031621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79837-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["79837"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-79837-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}